Detalhe da pesquisa
1.
A novel cell-cycle-regulated interaction of the Bloom syndrome helicase BLM with Mcm6 controls replication-linked processes.
Nucleic Acids Res
; 49(15): 8699-8713, 2021 09 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34370039
2.
Novel CD33 antibodies unravel localization, biology and therapeutic implications of CD33 isoforms.
Future Oncol
; 17(3): 263-277, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-33356566
3.
Genetic variation in DNA damage response pathway and response to Gemtuzumab Ozogamicin in pediatric AML: a report from the Children's Oncology Group.
Clin Cancer Res
; 2024 Jan 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38197878
4.
A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials.
Leukemia
; 36(8): 2022-2031, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35688939
5.
Cellular defects caused by hypomorphic variants of the Bloom syndrome helicase gene BLM.
Mol Genet Genomic Med
; 4(1): 106-19, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26788541